Lymphoma Trial Success
Genmab and AbbVie Report 51% Lower Lymphoma Progression Risk in Phase 3 Trial
Anonymous
Genmab and AbbVie reported that their Phase 3 EPCORE DLBCL-2 trial found epcoritamab, added to standard R-CHOP chemotherapy, reduced the risk of disease progression or death by 51% compared with R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients with higher-risk scores. The improvement in progression-free survival was statistically significant, and the combination’s safety profile was generally consistent with prior experience. The investigational regimen is not yet approved for this use; the companies plan to consult global regulators and present full trial data at a future medical meeting. The results could offer a new frontline treatment option for this aggressive lymphoma.
Key Points
1
EPCORE DLBCL-2 is the first Phase 3 trial to show a statistically significant and clinically meaningful progression-free-survival benefit from a bispecific-antibody combination in frontline DLBCL.
2
The global, open-label trial randomized patients 2:1: the combination arm received epcoritamab plus R-CHOP for six cycles, followed by epcoritamab alone for two cycles; the comparison arm received R-CHOP for six cycles, followed by rituximab for two cycles.
3
Epcoritamab is already approved in more than 65 countries for certain other lymphoma indications, marketed as Epkinly in the U.S. and Japan and Tepkinly in the EU.
4
DLBCL accounts for about 25–30% of non-Hodgkin lymphoma cases worldwide; roughly 25,000 new cases are diagnosed annually in the United States, according to the Leukemia and Lymphoma Society.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
29
Reach
46
Topics
A
AnonymousAuthor
